Reference number(s)	
1903-H	

SPECIALTY QUANTITY LIMIT PROGRAM

TYKERB (lapatinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tykerb (lapatinib) 250 mg tablets	180 tablets per 30 days	Breast cancer in combination with capecitabine: 1250 mg daily Breast cancer in combination with letrozole: 1500 mg daily

III. REFERENCE

1. Tykerb [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2017.

Specialty Quantity Limit Tykerb 1903-H P2019a

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of